TAA-T cells

Phase 1

CCatherine Bollard

TAA-T cells is one of 13 therapeutic programs targeting Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hodgkin LymphomaActive, not recruiting

Hodgkin LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

6 2

DTIC-Dome

Bayer

Phase 3

6 3

Adcetris

Pfizer

Phase 3

5 4

Velban

Eli Lilly

Phase 3

4 5

Adriamycin

Pfizer

Phase 3

3 6

Adriamycin

Pfizer

Phase 3

3 7

Keytruda

Merck & Co.

Phase 2

5 8

Gemzar

Johnson & Johnson

Phase 2

2 9

Beyfortus

BeiGene

Phase 2

1 10

Navelbine

PPierre Fabre Medicament

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Hodgkin Lymphoma

NCT03843294

Clinical

Trials by Indication[1]

Hodgkin Lymphoma1 trial

Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma

Active, not recruiting·CCatherine Bollard·Phase 1·NCT03843294·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAA-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TAA-T cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Catherine Bollard company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: CCatherine Bollard

TAA-T cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News